PMID- 30005852
OWN - NLM
STAT- MEDLINE
DCOM- 20190312
LR  - 20210122
IS  - 2210-7762 (Print)
VI  - 226-227
DP  - 2018 Oct
TI  - SH2B3 aberrations enriched in iAMP21 B lymphoblastic leukemia.
PG  - 30-35
LID - S2210-7762(18)30087-5 [pii]
LID - 10.1016/j.cancergen.2018.05.004 [doi]
AB  - Acute lymphoblastic leukemia (ALL) represents the most common childhood 
      malignancy. Although survival for pediatric B-ALL has approached 90%, variability 
      in outcome among and within cytogenetically defined subgroups persists. While 
      G-banding and fluorescence in situ hybridization (FISH) have been used to 
      characterize leukemic clones, there is added value of chromosomal microarray and 
      next generation sequencing in screening genome-wide for copy number aberrations, 
      copy neutral loss of heterozygosity and nucleotide variations. Evaluation of 
      novel genetic aberrations can provide information about the biologic mechanisms 
      of cytogenetically defined subgroups associated with poor prognosis, explain 
      heterogeneity in patient outcome and identify novel targets for therapeutic 
      intervention. The high risk B-ALL intrachromosomal amplification of chromosome 
      21, (iAMP21), subtype is characterized by amplification of a region of chromosome 
      21 that typically encompasses the RUNX1 gene and is associated with poor 
      prognosis. Analysis of chromosomal microarray and FISH data revealed that 
      deletions of SH2B3, encoding a negative regulator of multiple tyrosine kinase and 
      cytokine signaling pathways, are enriched among leukemias harboring iAMP21. 
      Enrichment of SH2B3 aberrations in the iAMP21 subtype may indicate that loss of 
      SH2B3 contributes to disease progression and raises the possibility that these 
      leukemias may be sensitive to tyrosine kinase inhibitors.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Baughn, L B
AU  - Baughn LB
AD  - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine 
      and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, United States.
FAU - Meredith, M M
AU  - Meredith MM
AD  - Department of Laboratory Medicine and Pathology and Masonic Cancer Center, 
      University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, United States.
FAU - Oseth, L
AU  - Oseth L
AD  - Department of Laboratory Medicine and Pathology and Masonic Cancer Center, 
      University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, United States.
FAU - Smolarek, T A
AU  - Smolarek TA
AD  - Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 
      Burnet Avenue, TCHRF 1042, Cincinnati, OH, United States.
FAU - Hirsch, B
AU  - Hirsch B
AD  - Department of Laboratory Medicine and Pathology and Masonic Cancer Center, 
      University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, United States. 
      Electronic address: hirsc003@umn.edu.
LA  - eng
GR  - P30 CA077598/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180608
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Proteins)
RN  - 0 (SH2B3 protein, human)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Aberrations
MH  - Chromosome Banding/methods
MH  - Chromosomes, Human, Pair 21/*genetics
MH  - Comparative Genomic Hybridization
MH  - Cytogenetics
MH  - Female
MH  - *Gene Amplification
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Intracellular Signaling Peptides and Proteins
MH  - Male
MH  - *Mutation
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics/pathology
MH  - Proteins/*genetics
OTO - NOTNLM
OT  - Acute lymphoblastic leukemia
OT  - Chromosomal microarray
OT  - SH2B3
OT  - iAMP21
EDAT- 2018/07/15 06:00
MHDA- 2019/03/13 06:00
CRDT- 2018/07/15 06:00
PHST- 2018/03/24 00:00 [received]
PHST- 2018/05/07 00:00 [revised]
PHST- 2018/05/19 00:00 [accepted]
PHST- 2018/07/15 06:00 [entrez]
PHST- 2018/07/15 06:00 [pubmed]
PHST- 2019/03/13 06:00 [medline]
AID - S2210-7762(18)30087-5 [pii]
AID - 10.1016/j.cancergen.2018.05.004 [doi]
PST - ppublish
SO  - Cancer Genet. 2018 Oct;226-227:30-35. doi: 10.1016/j.cancergen.2018.05.004. Epub 
      2018 Jun 8.